Very good post Chereb. In short, Korenko chose lymph nodes for the intial India trials as Lymphoma is a very common cancer, making recruitment of patients much easier, as well as there are numerous lymph nodes throughout the body, allowing for multiple injection sites within a single patient. The purpose of the intial trial is not to specifically cure and remove the cancer, as some misguided persons suggest to mislead others here. The purpose of the trial is to show the effacy of the radiogel treating the cancer within the lymph node and maintaining the desired safety margins. This was a brilliant decision by Korenko. My step-father passed away from lymphatic cancer. The doctor had removed the identified cancerous nodes, but within six months, an undetected seed had migrated to his brain in an inoperable area and he died quickly after. Could radiogel have saved him? Possibly but we will never know. But thank God now others are finally close to getting the opportunity. FDA should have approved this months ago but they have been foot dragging and stonewalling. Intentionally? I don't know buty own feeling is the current admin and FDA is corrupt has had their own agenda dictated by big pharma, lobbyist and insurance companies. Hopefully the new administration and change of the head of FDA makes a difference to allow innovative treatment to move forward. Thank goodness Korenko had the foresight to get the India trials started months ago. We should have the intial safety data report on the 5 patients soon and I've no doubt it will be very good. That data will supplement the IDE submission as FDA then won't have much reason to delay approval. It's going to be an epic and great year for Vivos and shareholders. Go $RDGL !!
Market Data 
Markets 
AI
